List of drugs used in MM with FDA approval and labeled indications
| Novel agents | Year approved | Indication (lines of therapy failed) | Approved in combination |
|---|---|---|---|
| Thalidomide | 1998 | NDMM | Dexamethasone |
| Bortezomib (IV and SC) | 2003 | NDMMRRMM | Melphalan/prednisone |
| Lendalidomide | 2005 | RRMM Maintenance | Dexamethasone |
| Carfilzomib | 2012 | RRMM (1–3) | Lenalidomide/dexamethasoneDaratumumab/dexamethasoneDexamethasone |
| Pomalidomide | 2013 | RRMM (2) | Dexamethasone |
| Panobinostat | 2015 | RRMM (2) | Bortezomib/dexamethasone |
| Daratumumab (IV and SC) | 2015 | NDMM | Lenalidomide/dexamethasone Bortezomib/melphalan/prednisone Bortezomib/melphalan/dexamethasone |
| RRMM (1) | Lenalidomide/dexamethasone Bortezomib/dexamethasone | ||
| RRMM (1–3) | Carfilzomib/dexamethasonePomalidomide/dexamethasone | ||
| Elotuzumab | 2015 | RRMM | Lenalidomide/dexamethasonePomalidomide/dexamethasone |
| Ixazomib | 2015 | RRMM | Lenalidomide/dexamethasone |
| Selinexor | 2019 | RRMM (1)RRMM (PR) | Bortezomib/dexamethasoneDexamethasone |
| Belantamabmafodotin | 2020 | RRMM (4) | |
| Isatuximab | 2020 | RRMM | Pomalidomide/dexamethasone |
| Cytotoxic chemotherapy | |||
| Cyclophospha-mide (IV and PO) | 1959 | MM (unspecified) | |
| Melphalan (IV and PO) | 1964 | PalliativeASCT | |
| Carmustine | 1977 | Palliative | Prednisone |
| Liposomal doxorubicin | 1995 | RRMM (1) | Bortezomib |
| Adjunctive therapy | |||
| Zoledronic acid | 1964 | ||
| Pamidronate | 1995 | ||
| Plerixafor | 2008 | ||
If no drugs listed in table under Approved in combination then approval was for use as single agent;
FDA approval includes use as single agent. PR: penta-refractory; IV: intravenous; SC: subcutaneous; PO: oral; NDMM: newly diagnosed multiple myeloma; RRMM: relapsed/refractory multiple myeloma. Check FDA website and company prescribing for up-to-date details